<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">34977282</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2352-1872</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>16</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Bone reports</Title>
          <ISOAbbreviation>Bone Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Adherence to bone health guidelines in patients with hormone receptor-positive early breast cancer: Status and clinical impact in a Swiss cohort experience.</ArticleTitle>
        <Pagination>
          <StartPage>101160</StartPage>
          <MedlinePgn>101160</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">101160</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bonr.2021.101160</ELocationID>
        <Abstract>
          <AbstractText Label="AIM" NlmCategory="OBJECTIVE">In patients with postmenopausal hormone receptor-positive breast cancer (ER + eBC), aromatase inhibitors (AIs) are widely used for effective relapse prevention. However, AIs reduce bone density and increase bone-related events (BREs). Alongside calcium and vitamin D3 supplementation, bisphosphonates and denosumab are well-known options for improving outcomes in bone health and breast cancer prognosis. This study aimed to evaluate the practice patterns of bone health guideline-based management in real-world patients with ER + eBC.</AbstractText>
          <AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">In total, 68 patients with ER + eBC treated between 2009 and 2014 at the University Hospital Basel were included in this retrospective cohort study. Chart reviews were analyzed. Baseline, clinicopathological, treatment, and BRE data were extracted. Each patient was specifically reviewed for therapy adherence to the Swiss bone health guidelines (Swiss Association against Osteoporosis 2010 [SVGO]).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean patient age was 66.5 (range, 56-74) years, all post-menopausal. The most frequent tumor characteristics were tumor size of pT1-pT2 (N = 53, 77.9%) and treatment with letrozole (N = 35, 51.5%), followed by tamoxifen as a switch strategy (N = 27, 40.3%). The median treatment time with AIs was 47 (range, 30-60) months. Five patients (7.8%) experienced a fracture during or after AI treatment. Moreover, 51 (75%) patients were treated according to the SVGO recommendations.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The fracture rate in our retrospective cohort was comparable to that in the larger phase III randomized trials. The adherence to bone health guidelines was satisfactory but still suboptimal. Clinicians should strictly adhere to the current bone health guidelines to ensure the best possible prevention of BREs and maintain bone health and cancer prognosis in patients with ER + eBC.</AbstractText>
          <CopyrightInformation>© 2021 The Authors. Published by Elsevier Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bischof</LastName>
            <ForeName>Evelyne</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Shanghai University of Medicine and Health Sciences, Department of Basic and Clinical Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schwab</LastName>
            <ForeName>Fabienne D</ForeName>
            <Initials>FD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynaecologic Oncology, Women's Hospital, University Hospital Basel, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Georgescu Margarint</LastName>
            <ForeName>Elena Laura</ForeName>
            <Initials>EL</Initials>
            <AffiliationInfo>
              <Affiliation>Shanghai East International Medical Center, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Montavon</LastName>
            <ForeName>Céline</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynaecologic Oncology, Women's Hospital, University Hospital Basel, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zünti</LastName>
            <ForeName>Iris</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schollbach</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schötzau</LastName>
            <ForeName>Andreas</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynaecologic Oncology, Women's Hospital, University Hospital Basel, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirschmann</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, University Hospital Basel, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Landin</LastName>
            <ForeName>Julia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meier</LastName>
            <ForeName>Christian</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Christian</LastName>
            <ForeName>Kurzeder</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynaecologic Oncology, Women's Hospital, University Hospital Basel, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vetter</LastName>
            <ForeName>Marcus</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medical University Clinic, Canton Hospital Baselland, Liestal, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Bone Rep</MedlineTA>
        <NlmUniqueID>101646176</NlmUniqueID>
        <ISSNLinking>2352-1872</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Aromatase inhibitor</Keyword>
        <Keyword MajorTopicYN="N">Bisphosphonates</Keyword>
        <Keyword MajorTopicYN="N">Bone targeted therapies</Keyword>
        <Keyword MajorTopicYN="N">Breast cancer</Keyword>
        <Keyword MajorTopicYN="N">Calcium</Keyword>
        <Keyword MajorTopicYN="N">Denosumab</Keyword>
        <Keyword MajorTopicYN="N">Oncology</Keyword>
        <Keyword MajorTopicYN="N">Osteoporosis</Keyword>
        <Keyword MajorTopicYN="N">Postmenopause</Keyword>
        <Keyword MajorTopicYN="N">Public health</Keyword>
        <Keyword MajorTopicYN="N">Vitamin D</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>49</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34977282</ArticleId>
        <ArticleId IdType="pmc">PMC8685978</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bonr.2021.101160</ArticleId>
        <ArticleId IdType="pii">S2352-1872(21)00417-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Amir E., Ocaña A., Seruga B., Josse R., Clemons M. Medical oncology: zoledronic acid for breast cancer therapy-induced bone loss. Nat. Rev. Clin. Oncol. 2010;7(4):187–188. doi: 10.1038/nrclinonc.2010.19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2010.19</ArticleId>
            <ArticleId IdType="pubmed">20354540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bošković L., Gašparić M., Petković M., et al.  Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors. Breast. 2017;31:16–19. doi: 10.1016/j.breast.2016.10.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.breast.2016.10.018</ArticleId>
            <ArticleId IdType="pubmed">27810693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brufsky A., Harker W.G., Beck J.T., et al.  Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J. Clin. Oncol. 2007;25(7):829–836. doi: 10.1200/jco.2005.05.3744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2005.05.3744</ArticleId>
            <ArticleId IdType="pubmed">17159193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheung a.M., Tile L., Cardew S., et al.  Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol. 2012;13(3):275–284. doi: 10.1016/S1470-2045(11)70389-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(11)70389-8</ArticleId>
            <ArticleId IdType="pubmed">22318095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chien A.J., Goss P.E. Aromatase inhibitors and bone health in women with breast cancer. J. Clin. Oncol. 2006;24(33):5305–5312. doi: 10.1200/JCO.2006.07.5382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2006.07.5382</ArticleId>
            <ArticleId IdType="pubmed">17114665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen A., Fleischer J.B., Johnson M.K., et al.  Prevention of bone loss after withdrawal of tamoxifen. Endocr. Pract. 2008;14(2):162–167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3140137</ArticleId>
            <ArticleId IdType="pubmed">18308653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coleman R.E., Banks L.M., Girgis S.I., et al.  Reversal of skeletal effects of endocrine treatments in the intergroup exemestane study. Breast Cancer Res. Treat. 2010;124(1):153–161. doi: 10.1007/s10549-010-1121-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-010-1121-7</ArticleId>
            <ArticleId IdType="pubmed">20730486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coleman R., De Boer R., Eidtmann H., et al.  Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Annals of Oncology. 2013 doi: 10.1093/annonc/mds277. Published online.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mds277</ArticleId>
            <ArticleId IdType="pubmed">23047045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhesy-thind S.K., Centre J.C.  Screening for Osteoporosis in Postmenopausal Women With Breast Cancer Receiving Aromatase Inhibitors: Less Is More. 30(13) 2012. pp. 1408–1410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22370320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ellis G.K., Bone H.G., Chlebowski R., et al.  Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res. Treat. 2009;118(1):81–87. doi: 10.1007/s10549-009-0352-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-009-0352-y</ArticleId>
            <ArticleId IdType="pubmed">19308727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gnant M.F.X., Mlineritsch B., Luschin-Ebengreuth G., et al.  Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J. Clin. Oncol. 2007;25(7):820–828. doi: 10.1200/JCO.2005.02.7102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2005.02.7102</ArticleId>
            <ArticleId IdType="pubmed">17159195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gralow J.R. Bone density in breast cancer: when to intervene? J. Clin. Oncol. 2007;25(22):3194–3197. doi: 10.1200/JCO.2007.12.3430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2007.12.3430</ArticleId>
            <ArticleId IdType="pubmed">17577014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gralow J.R., Biermann J.S., Farooki A., et al.  NCCN task force report: bone health in cancer care. J. Natl. Compr. Cancer Netw. 2009;7(Suppl. 3):1–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3047404</ArticleId>
            <ArticleId IdType="pubmed">19555589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadji P., Aapro M.S., Body J.J., et al.  Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann. Oncol. 2011;22(12):2546–2555. doi: 10.1093/annonc/mdr017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdr017</ArticleId>
            <ArticleId IdType="pubmed">21415233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadji P., Klein S., Gothe H., et al.  The epidemiology of osteoporosis–bone evaluation study (BEST): an analysis of routine health insurance data. Dtsch. Arztebl. Int. 2013;110(4):52–57. doi: 10.3238/arztebl.2013.0052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3238/arztebl.2013.0052</ArticleId>
            <ArticleId IdType="pmc">PMC3570954</ArticleId>
            <ArticleId IdType="pubmed">23413388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irwin M.L., Alvarez-Reeves M., Cadmus L., et al.  Exercise improves body fat, lean mass and bone mass in breast cancer survivors. Obesity (Silver Spring) 2009;17(8):1534–1541. doi: 10.1038/oby.2009.18.Exercise.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/oby.2009.18.Exercise</ArticleId>
            <ArticleId IdType="pmc">PMC2841468</ArticleId>
            <ArticleId IdType="pubmed">19629060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones S., Stokoe C., Sborov M., et al.  The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer. Clin. Breast Cancer. 2008;8(6):527–532. doi: 10.3816/CBC.2008.n.065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3816/CBC.2008.n.065</ArticleId>
            <ArticleId IdType="pubmed">19073509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kilbreath S., Refshauge K.M., Beith J., et al.  Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: rationale and design of a randomized controlled trial. Contemp Clin Trials. 2011;32(5):704–709. doi: 10.1016/j.cct.2011.04.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cct.2011.04.012</ArticleId>
            <ArticleId IdType="pubmed">21570487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knobf M.T., Insogna K., DiPietro L., Fennie K., Thompson A.S. An aerobic weight-loaded pilot excercise intervention for breast cancer survivors: bone remodelling and body composition outcomes. Biol. Res. Nurs. 2008;10(1):34–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3540790</ArticleId>
            <ArticleId IdType="pubmed">18705153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Link H., Diel I., Ohlmann C.H., Holtmann L., Kerkmann M. Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany. Supportive Care in Cancer. 2019 doi: 10.1007/s00520-019-05018-2. Published online.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00520-019-05018-2</ArticleId>
            <ArticleId IdType="pmc">PMC7083811</ArticleId>
            <ArticleId IdType="pubmed">31410600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lunt M., Felsenber D., Adms J., Benevolenkaya L., et al.  International original article population-based geographic variations in DXA bone density in Europe: the EVOS study. Osteoporos. Int. 1997;7(3):175–189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9205628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muslimani A.a., Spiro T.P., Taylor H.C., Jaiyesimi I., Daw H.a. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms? Clin. Breast Cancer. 2009;9(1):34–38. doi: 10.3816/CBC.2009.n.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3816/CBC.2009.n.006</ArticleId>
            <ArticleId IdType="pubmed">19299238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noon E., Singh S., Cuzick J., et al.  Significant differences in UK and US female bone density reference ranges. Osteoporos. Int. 2010;21(11):1871–1880. doi: 10.1007/s00198-009-1153-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00198-009-1153-1</ArticleId>
            <ArticleId IdType="pmc">PMC3605787</ArticleId>
            <ArticleId IdType="pubmed">20063090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onishi T., Hayashi N., Theriault R.L., Hortobagyi G.N., Ueno N.T. Future directions of bone-targeted therapy for metastatic breast cancer. Nat. Rev. Clin. Oncol. 2010;7(11):641–651. doi: 10.1038/nrclinonc.2010.134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2010.134</ArticleId>
            <ArticleId IdType="pubmed">20808302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powles B.T.J., Hickish T., Kanis J.A., Tidy A., Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. American society of. Clin. Oncol. 1996;14(I):78–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8558225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Regan M.M., Price K.N., Giobbie-hurder A., Thürlimann B., Gelber R.D. Interpreting Breast International Group (BIG) 1–98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res. 2011;13(209):1–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3218925</ArticleId>
            <ArticleId IdType="pubmed">21635709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reid D.M., Doughty J., Eastell R., et al.  Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat. Rev. 2008;34(Suppl. 1):3–18. doi: 10.1016/j.ctrv.2008.03.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2008.03.007</ArticleId>
            <ArticleId IdType="pubmed">18515009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodan G.A., Fleisch H.A., et al.  Bisphosphonates. Mechanisms of action. Jounal of Clinical Investigation. 1996;97(12):2692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC507360</ArticleId>
            <ArticleId IdType="pubmed">8675678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rozenberg S., Carly B., Liebens F., Antoine C. Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment. Maturitas. 2009;64(1):1–3. doi: 10.1016/j.maturitas.2009.07.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.maturitas.2009.07.012</ArticleId>
            <ArticleId IdType="pubmed">19709824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruhstaller T., Giobbie-Hurder A., Colleoni M., et al.  Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BiG 1–98 trial. Journal of Clinical Oncology. 2019 doi: 10.1200/JCO.18.00440. Published online.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.18.00440</ArticleId>
            <ArticleId IdType="pmc">PMC6325353</ArticleId>
            <ArticleId IdType="pubmed">30475668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salmen J., Banys-Paluchowski M., Fehm T. Bone-targeted therapy. Geburtshilfe Frauenheilkd. 2015;75(6):584–587. doi: 10.1055/s-0035-1546151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0035-1546151</ArticleId>
            <ArticleId IdType="pmc">PMC4490911</ArticleId>
            <ArticleId IdType="pubmed">26166839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sambrook P., Cooper C. Osteoporosis. Lancet. 2006;367(9527):2010–2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16782492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schweiz Krebsliga. Krebs in Der Schweiz Wichtige Zahlen. vol. 2013. 2016. pp. 2009–2013.</Citation>
        </Reference>
        <Reference>
          <Citation>Stute P., Birkhaüser M., Wolff M., Meier C. Gynaecologists' awareness of bone healthcare in Switzerland. Swiss Medical Weekly. 2014 doi: 10.4414/smw.2014.13931. Published online.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4414/smw.2014.13931</ArticleId>
            <ArticleId IdType="pubmed">24573548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swenson K.K., Nissen M.J., Anderson E., Shapiro a., Schousboe J., Leach J. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy. J Support Oncol. 2009;7(3):101–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19507458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabane K., Vorobiof D.A. Bone targeted therapies in early breast cancer. Curr. Treat. Options in Oncol. 2011;12(4):412–423. doi: 10.1007/s11864-011-0163-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11864-011-0163-3</ArticleId>
            <ArticleId IdType="pubmed">21887503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thurlimann B., Keshaviah A., Coates A.S., et al.  A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 2005;353(26):2747–2757. doi: 10.1056/NEJMoa052258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa052258</ArticleId>
            <ArticleId IdType="pubmed">16382061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zekri J., Farag K. Assessment of bone health in breast cancer patients starting adjuvant aromatase inhibitors: a quality improvement clinical audit. J. Bone Oncol. 2016;5(4):159–162. doi: 10.1016/j.jbo.2016.05.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jbo.2016.05.007</ArticleId>
            <ArticleId IdType="pmc">PMC5154697</ArticleId>
            <ArticleId IdType="pubmed">28008376</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
